Payment overview · 2025
General Payments
$395.33
15 reported records · 8 companies
Healthcare provider profile · identity verified
Fitzclaud Grant, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ELMONT, NY · NPI 1194893990
Verified facts
What the public records show
CMS Open Payments records show Fitzclaud Grant, M.D. received $395.33 in general payments during 2025 across 15 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 22.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Edarbi, Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Farxiga by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Edarbi by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBYCLOR as an associated drug or biological on 283 records involving 215 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Edarbyclor by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $90.72 | 22.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $71.59 | 18.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.86 | 13.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $48.71 | 12.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $47.24 | 11.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.45 | 8.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $29.34 | 7.4% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.42 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $395.33 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $90.72 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $54.62 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $33.45 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.45 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.91 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $29.34 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $27.42 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $25.35 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $22.42 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $18.95 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.95 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| EDARBI edarbi |
2025 | Edarbi | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 88 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
74 | 16 |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBYCLOR open payments reported associated product |
CMS Open Payments — General Payments 283 supporting records · 215 recipient NPIs · example record 1242666846 |
Edarbyclor · 2024 Exact normalized brand match · 1 Part D row |
93 | 24 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 464 | 139 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 336 | 110 |
| Atorvastatin Calcium | Atorvastatin Calcium | 276 | 85 |
| Losartan Potassium | Losartan Potassium | 252 | 76 |
| Metformin Hcl | Metformin Hcl | 178 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 137 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 132 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 119 | 35 |
| Levothyroxine Sodium | Levothyroxine Sodium | 111 | 31 |
| Simvastatin | Simvastatin | 107 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 107 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 31 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 93 | 24 |
| Jardiance | Empagliflozin | 88 | 23 |
| Gabapentin | Gabapentin | 86 | 26 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 76 | 18 |
| Farxiga | Dapagliflozin Propanediol | 74 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 65 | 23 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 65 | 19 |
| Januvia | Sitagliptin Phosphate | 62 | 17 |
| Azithromycin | Azithromycin | 50 | 38 |
| Donepezil Hcl | Donepezil Hcl | 49 | 13 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 49 | 14 |
| Eliquis | Apixaban | 48 | 14 |
| Valsartan | Valsartan | 46 | 13 |
| Lisinopril | Lisinopril | 43 | 11 |
| Metformin Hcl Er | Metformin Hcl | 43 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 40 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 39 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 25 |
| Nebivolol Hcl | Nebivolol Hcl | 38 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 38 | 11 |
| Atenolol | Atenolol | 37 | 11 |
| Potassium Chloride | Potassium Chloride | 37 | 11 |
| Pregabalin | Pregabalin | 37 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 36 | suppressed |
| Telmisartan | Telmisartan | 36 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 35 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 19 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 33 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Furosemide | Furosemide | 32 | 13 |
| Methylprednisolone | Methylprednisolone | 32 | 12 |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Naproxen | Naproxen | 29 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Famotidine | Famotidine | 28 | suppressed |
| Omeprazole | Omeprazole | 28 | suppressed |
| Allopurinol | Allopurinol | 27 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 26 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 13 |
| Glimepiride | Glimepiride | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Fluocinonide | Fluocinonide | 23 | 15 |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Alprazolam | Alprazolam | 21 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Meloxicam | Meloxicam | 21 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Carvedilol | Carvedilol | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Repaglinide | Repaglinide | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Edarbi | Azilsartan Medoxomil | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $395.33 · 15 records | Boehringer Ingelheim Pharmaceuticals, Inc. | AIRSUPRA, AREXVY, Cologuard Collection Kit, EDARBI, FASENRA, FREESTYLE LIBRE 3, JARDIANCE, Ozempic, QULIPTA, SHINGRIX, Saxenda, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, Wegovy | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Edarbi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error